{"id":529,"date":"2026-02-26T17:24:28","date_gmt":"2026-02-26T15:24:28","guid":{"rendered":"http:\/\/example.test\/?page_id=529"},"modified":"2026-05-07T12:52:21","modified_gmt":"2026-05-07T09:52:21","slug":"glp-1-metabolic-research-guide","status":"publish","type":"page","link":"https:\/\/life-peptide.com\/ro\/glp-1-metabolic-research-guide\/","title":{"rendered":"Agoni\u0219ti GLP-1, duali \u0219i tripli \u00een cercetarea metabolic\u0103"},"content":{"rendered":"<h1 class=\"wp-block-heading has-text-align-center\">Agoni\u0219ti GLP-1, duali \u0219i tripli \u00een cercetarea metabolic\u0103<\/h1>\n\n\n\n<h2 class=\"wp-block-heading has-text-align-center\">Mecanisme, inginerie structural\u0103 \u0219i analiz\u0103 comparativ\u0103<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Peptidele metabolice care vizeaz\u0103 c\u0103ile incretinice reprezint\u0103 una dintre cele mai intensive zone de cercetare \u00een endocrinologia modern\u0103 \u0219i \u00een cercetarea regl\u0103rii energiei. Agoni\u0219tii receptorilor GLP-1 \u0219i analogii multi-agoni\u0219ti sunt investiga\u021bi pe scar\u0103 larg\u0103 pentru rolul lor \u00een homeostazia glucozei, semnalizarea apetitului, metabolismul lipidic \u0219i reglarea energetic\u0103 sistemic\u0103.<br>Acest ghid ofer\u0103 o prezentare structurat\u0103 a:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Semnalizarea receptorului GLP-1<\/li>\n\n\n\n<li>Agoni\u0219ti duali de incretin\u0103 (GLP-1 + GIP)<\/li>\n\n\n\n<li>Agoni\u0219ti tripli (GLP-1 + GIP + glucagon)<\/li>\n\n\n\n<li>Modific\u0103ri structurale pentru o perioad\u0103 de \u00eenjum\u0103t\u0103\u021bire extins\u0103<\/li>\n\n\n\n<li>Diferen\u021be comparative \u00een c\u0103ile de semnalizare ale receptorilor<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Pentru compu\u0219ii disponibili din aceast\u0103 categorie, vezi <strong><a href=\"\/ro\/category\/peptidi-de-cercetare-metabolica\/\" data-type=\"product_cat\" data-id=\"19\">Peptide metabolice<\/a><\/strong> colec\u021bie.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">1. <strong>Reglarea metabolic\u0103 \u0219i rezultatele greut\u0103\u021bii corporale \u00een modele de cercetare<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Agoni\u0219tii receptorilor pentru peptidul glucagon-like-1 (GLP-1) sunt studia\u021bi pe scar\u0103 larg\u0103 \u00een medii de cercetare controlate, investig\u00e2nd reglarea metabolic\u0103 \u0219i rezultatele legate de greutatea corporal\u0103. Aceste compu\u0219i prezint\u0103 un interes deosebit datorit\u0103 interac\u021biunii lor cu c\u0103ile de semnalizare implicate \u00een modularea apetitului, echilibrul energetic \u0219i metabolismul nutrien\u021bilor.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u00cen modele experimentale, activarea c\u0103ii GLP-1 a fost asociat\u0103 cu modific\u0103ri m\u0103surabile ale unor parametri precum semnalizarea aportului caloric, dinamica golirii gastrice \u0219i r\u0103spunsul insulinic dependent de glucoz\u0103. Aceste mecanisme sunt analizate frecvent \u00een contextul proceselor metabolice mai ample, incluz\u00e2nd homeostazia energetic\u0103 \u0219i reglarea compozi\u021biei corporale.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Un num\u0103r tot mai mare de cercet\u0103ri examineaz\u0103, de asemenea, modul \u00een care activitatea receptorilor GLP-1 interac\u021bioneaz\u0103 cu c\u0103i complementare, cum ar fi cele ale peptidului insulinotropic dependent de glucoz\u0103 (GIP) \u0219i semnalizarea glucagonului. Compu\u015fii multi-agoni\u0219ti, inclusiv agonii\u0219ti duali \u0219i tripli ai receptorilor, sunt investiga\u021bi pentru efectele lor combinate asupra eficien\u021bei metabolice \u0219i utiliz\u0103rii energiei sistemice.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u00cen acest context, agoni\u0219tii receptorilor GLP-1 sunt frecvent inclu\u0219i \u00een modelele de cercetare care exploreaz\u0103 c\u0103ile metabolice asociate cu pierderea \u00een greutate, \u00een special cele legate de reglarea apetitului \u0219i modularea aportului energetic. Aceste investiga\u021bii se concentreaz\u0103 pe rezultate mecanistice, mai degrab\u0103 dec\u00e2t pe aplica\u021bii terapeutice, cu accent pe interac\u021biunile la nivel de c\u0103i \u0219i r\u0103spunsurile biologice m\u0103surabile.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u00cen\u021belegerea acestor mecanisme ofer\u0103 un cadru structurat pentru analiza modului \u00een care diferite clase de peptide influen\u021beaz\u0103 parametrii metabolici \u00een diverse condi\u021bii experimentale.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<h3 class=\"wp-block-heading\">2. Sistemul incretinic: mecanism de baz\u0103<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Peptida asem\u0103n\u0103toare glucagonului-1 (GLP-1) este un hormon endogen secretat de celulele intestinale L dup\u0103 aportul de nutrien\u021bi. Se leag\u0103 de receptorii GLP-1 localiza\u021bi \u00een celulele beta pancreatice, \u021besut gastrointestinal, \u021besut cardiovascular \u0219i regiuni ale sistemului nervos central.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Activarea receptorului GLP-1 este asociat\u0103 cu:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Secre\u021bia de insulin\u0103 dependent\u0103 de glucoz\u0103<\/li>\n\n\n\n<li>Suprimarea eliber\u0103rii de glucagon<\/li>\n\n\n\n<li>Golire gastric\u0103 \u00eent\u00e2rziat\u0103<\/li>\n\n\n\n<li>Reglare central\u0103 a apetitului<\/li>\n\n\n\n<li>Modularea metabolismului hepatic al lipidelor<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">GLP-1 nativ este rapid degradat de dipeptidil peptidaza-4 (DPP-4), rezult\u00e2nd un timp de \u00eenjum\u0103t\u0103\u021bire plasmatic\u0103 de aproximativ 1-2 minute. Datorit\u0103 acestei limit\u0103ri, analogi sintetici au fost proiecta\u021bi pentru a rezista degrad\u0103rii enzimatice \u0219i pentru a prelungi activarea receptorilor.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Rolul fiziologic al semnaliz\u0103rii receptorilor GLP-1 \u00een controlul glucozei \u0219i reglarea apetitului a fost documentat extensiv \u00een literatura de cercetare metabolic\u0103 (Drucker, 2018; Nauck &amp; Meier, 2019).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">3. Agoni\u0219ti ai receptorilor GLP-1 (activarea unei singure c\u0103i)<\/h3>\n\n\n\n<h4 class=\"wp-block-heading\">Semaglutid\u0103<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Semaglutida este un analog GLP-1 cu ac\u021biune prelungit\u0103, inginerit prin:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Substitu\u021bie de aminoacizi pentru rezisten\u021ba la DPP-4<\/li>\n\n\n\n<li>Conjugarea lan\u021bului lateral al acizilor gra\u0219i pentru legarea albuminei<\/li>\n\n\n\n<li>Afinare crescut\u0103 a receptorilor<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Legarea de albumin\u0103 prelunge\u0219te semnificativ \u00eenjum\u0103t\u0103\u021birea \u0219i stabilizeaz\u0103 concentra\u021bia peptidelor circulante, permi\u021b\u00e2nd activarea sus\u021binut\u0103 a receptorilor \u00een modele de cercetare.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Studii clinice \u0219i de transla\u021bie au demonstrat c\u0103 agoni\u0219tii cu ac\u021biune prelungit\u0103 ai receptorilor GLP-1 \u00eembun\u0103t\u0103\u021besc controlul glicemic \u0219i influen\u021beaz\u0103 semnificativ reglarea greut\u0103\u021bii corporale (Wilding et al., 2021; Marso et al., 2016).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u00cen contexte de cercetare metabolic\u0103, semaglutida reprezint\u0103 o <strong>model de incretin\u0103 focalizat, pe o singur\u0103 cale<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Vizualiza\u021bi specifica\u021bii detaliate pentru <strong><a href=\"\/ro\/product\/semaglutide-10-mg\/\" data-type=\"product\" data-id=\"303\">Peptid\u0103 de cercetare Semaglutid\u0103 10 mg<\/a><\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">4. Agoni\u0219ti duali: activarea GLP-1 + GIP<\/h3>\n\n\n\n<h4 class=\"wp-block-heading\">Exemplu: Tirzepatid\u0103<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Tirzepatida este un agonist dual care activeaz\u0103 ambele:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Receptori GLP-1<\/li>\n\n\n\n<li>Receptori GIP (polipeptid insulinotrop dependent de glucoz\u0103)<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">GIP este un alt hormon incretinic implicat \u00een secre\u021bia de insulin\u0103 \u0219i \u00een reglarea metabolic\u0103 a adipocitelor. Agonismul dual permite investigarea semnaliz\u0103rii sinergice a incretinelor.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Cercet\u0103rile au demonstrat c\u0103 activarea combinat\u0103 a receptorilor GLP-1 \u0219i GIP produce efecte metabolice sporite comparativ cu activarea doar a receptorilor GLP-1 (Frias et al., 2021; Jastreboff et al., 2022).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Stimularea pe dou\u0103 c\u0103i permite:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Semnalizare insulinotropic\u0103 extins\u0103<\/li>\n\n\n\n<li>R\u0103spunsuri alterate ale \u021besutului adipos<\/li>\n\n\n\n<li>Complexitate sporit\u0103 a model\u0103rii metabolice<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Tirzepatida reprezint\u0103, a\u0219adar, o <strong>model avansat de cercetare a incretinelor<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Exploreaz\u0103 profilul complet al <strong><a href=\"\/ro\/product\/tirzepatide-10-mg\/\" data-type=\"product\" data-id=\"309\">Peptid\u0103 de cercetare Tirzepatide<\/a><\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">5. Agoni\u0219ti tripli: GLP-1 + GIP + Glucagon<\/h3>\n\n\n\n<h4 class=\"wp-block-heading\">Retatrutid\u0103<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Retatrutida extinde semnalizarea mai departe prin activarea:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Receptori GLP-1<\/li>\n\n\n\n<li>Receptori GIP<\/li>\n\n\n\n<li>Receptori de glucagon<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Angajarea receptorului de glucagon introduce reglarea metabolic\u0103 hepatic\u0103 \u00een modelul de semnalizare, influen\u021b\u00e2nd:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>C\u0103i de cheltuire a energiei<\/li>\n\n\n\n<li>Semnalizare prin oxidarea lipidelor<\/li>\n\n\n\n<li>Dinamica produc\u021biei hepatice de glucoz\u0103<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Faza 2 a cercet\u0103rii care investigheaz\u0103 triplul agonism a demonstrat o modulare metabolic\u0103 semnificativ\u0103 \u0219i efecte pronun\u021bate asupra greut\u0103\u021bii corporale \u0219i parametrilor glicemici (Jastreboff et al., 2023).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Agoni\u0219tii tripli reprezint\u0103 o <strong>cadru de cercetare metabolic\u0103 de \u00eenalt\u0103 complexitate<\/strong>, integr\u00e2nd c\u0103ile incretinice \u0219i hepatice endocrine.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Vezi detalii tehnice pentru <a href=\"\/ro\/product\/retatrutide-10-mg\/\" data-type=\"product\" data-id=\"331\"><strong>Analogie cu agonist triplu Retatrutide<\/strong>.<\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\">6. Ingineria structural\u0103 a analogilor cu ac\u021biune prelungit\u0103<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Analoagele moderne de incretin\u0103 \u00eencorporeaz\u0103 modific\u0103ri moleculare \u021bintite, inclusiv:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Substitu\u021bii la pozi\u021bii aminoacizilor vulnerabili enzimatic<\/li>\n\n\n\n<li>Lipidare pentru asociere cu albumina<\/li>\n\n\n\n<li>Structur\u0103 secundar\u0103 stabilizat\u0103 pentru men\u021binerea afinit\u0103\u021bii receptorului<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Aceste strategii de inginerie:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>\u00cembun\u0103t\u0103\u021bi\u021bi rezisten\u021ba la degradarea DPP-4<\/li>\n\n\n\n<li>Prelunge\u0219te timpul de \u00eenjum\u0103t\u0103\u021bire \u00een circula\u021bie<\/li>\n\n\n\n<li>Activarea model\u0103rii farmacocinetice predictibile<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Aceste adapt\u0103ri structurale diferen\u021biaz\u0103 analogii de cercetare de hormonii incretinici nativi \u0219i permit ferestre experimentale extinse.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">7. Prezentare comparativ\u0103<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>Caracteristic\u0103<\/strong><\/td><td><strong>Agonist GLP-1<\/strong><\/td><td><strong>Agonist Dual<\/strong><\/td><td><strong>Agonist triplu<\/strong><\/td><\/tr><\/thead><tbody><tr><td>Receptori \u021binti\u021bi<\/td><td>GLP-1<\/td><td>GLP-1 + GIP<\/td><td>GLP-1 + GIP + Glucagon<\/td><\/tr><tr><td>L\u0103\u021bimea semnaliz\u0103rii<\/td><td>Concentrat<\/td><td>Incretine amplificate<\/td><td>Sistemic cu mai multe c\u0103i<\/td><\/tr><tr><td>Complexitatea cercet\u0103rii<\/td><td>Moderat<\/td><td>Avansat<\/td><td>Sus<\/td><\/tr><tr><td>Domeniul metabolic<\/td><td>Pofta de m\u00e2ncare + glucoz\u0103<\/td><td>Sinergie crescut\u0103 a incretinelor<\/td><td>Incretine + modula\u021bie hepatic\u0103<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Pe m\u0103sur\u0103 ce implicarea receptorilor cre\u0219te, complexitatea semnaliz\u0103rii descendente se extinde. Modelele experimentale trebuie s\u0103 ia \u00een considerare crosstalk-ul receptorilor, mecanismele hormonale compensatorii \u0219i sistemele de feedback metabolic.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">8. Considera\u021bii privind manipularea \u00een laborator<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">C\u00e2nd lucra\u021bi cu analogi de incretin\u0103 liofiliza\u021bi:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>P\u0103stra\u021bi la 2\u20138 \u00b0C<\/li>\n\n\n\n<li>A se feri de lumin\u0103<\/li>\n\n\n\n<li>Utiliza\u021bi tehnica de reconstituire steril\u0103<\/li>\n\n\n\n<li>Evita\u021bi ciclurile repetate de \u00eenghe\u021b-dezghe\u021b<\/li>\n\n\n\n<li>Men\u021bine trasabilitatea lotului<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Manipularea corect\u0103 p\u0103streaz\u0103 stabilitatea peptidelor \u0219i asigur\u0103 condi\u021bii experimentale reproductibile.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">9. \u00centreb\u0103ri frecvente<\/h3>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Rolul GLP-1 \u00een cercetarea metabolic\u0103<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">GLP-1 este o peptid\u0103 semnalizatoare studiat\u0103 pentru rolul s\u0103u \u00een metabolismul glucozei, r\u0103spunsul la insulin\u0103 \u0219i reglarea apetitului. \u00cen mediile de cercetare, este utilizat pentru a investiga modul \u00een care c\u0103ile de semnalizare hormonal\u0103 influen\u021beaz\u0103 echilibrul energetic \u0219i func\u021bia metabolic\u0103.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Cum sunt studia\u021bi agon\u0219tii receptorilor GLP-1 \u00een modele de cercetare?<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Agoni\u0219tii receptorilor GLP-1 sunt analiza\u021bi \u00een medii controlate pentru a evalua efectele lor asupra unor parametri precum semnalizarea aportului caloric, golirea gastric\u0103 \u0219i activitatea insulinei dependent\u0103 de glucoz\u0103. Aceste studii se concentreaz\u0103 pe r\u0103spunsuri biologice m\u0103surabile, mai degrab\u0103 dec\u00e2t pe rezultate clinice.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>C\u0103ile GLP-1 sunt conectate la reglarea greut\u0103\u021bii corporale?<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Da. Semnalizarea GLP-1 este frecvent examinat\u0103 \u00een modele de cercetare care exploreaz\u0103 rezultate legate de greutatea corporal\u0103, \u00een special prin interac\u021biunea sa cu mecanismele de reglare a apetitului \u0219i de aport energetic.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Care este diferen\u021ba dintre c\u0103ile GLP-1, GIP \u0219i glucagon?<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">GLP-1 influen\u021beaz\u0103 \u00een principal secre\u021bia de insulin\u0103 \u0219i semnalizarea apetitului, GIP este asociat cu r\u0103spunsul insulinei dependent de nutrien\u021bi, iar glucagonul este implicat \u00een mobilizarea glucozei. Compu\u015fii multi-agoni\u0219ti sunt studia\u021bi pentru efectele lor combinate \u00een aceste c\u0103i.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>De ce sunt studiate peptidele multi-agoniste?<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Agoni\u0219tii duali \u0219i tripli sunt investiga\u021bi pentru a \u00een\u021belege cum activarea simultan\u0103 a mai multor c\u0103i metabolice poate influen\u021ba echilibrul energetic general, eficien\u021ba metabolic\u0103 \u0219i interac\u021biunile sistemice de semnalizare.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Aceste compu\u0219i cauzeaz\u0103 \u00een mod direct pierderea \u00een greutate?<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Cercetarea se concentreaz\u0103 pe c\u0103ile metabolice \u0219i mecanismele de semnalizare, mai degrab\u0103 dec\u00e2t pe rezultatele la oameni. Observa\u021biile legate de greutatea corporal\u0103 sunt studiate ca parte a unor modele metabolice mai ample, nu ca efecte independente.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>De ce sunt necesare analogi sintetici \u00een loc de GLP-1 nativ?<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">GLP-1 nativ este degradat rapid de enzimele DPP-4. Modificarea structural\u0103 extinde stabilitatea \u0219i permite activarea sus\u021binut\u0103 a receptorilor \u00een medii de cercetare controlate.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Sunt aceste compu\u0219i furniza\u021bi pentru consum uman?<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Nu. Toate peptidele men\u021bionate sunt furnizate strict \u00een scopuri de cercetare de laborator \u0219i analitic\u0103.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Cum ar trebui determinat\u0103 selec\u021bia compu\u0219ilor?<\/strong><\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Studiu axat pe calea incretinic\u0103 \u2192 Agonist GLP-1<\/li>\n\n\n\n<li>Cercetare extins\u0103 asupra sinergiei incretinelor \u2192 Agonist dual<\/li>\n\n\n\n<li>Modelarea metabolic\u0103 sistemic\u0103 \u2192 Agonist triplu<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">10. Referin\u021be \u0219tiin\u021bifice<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Drucker DJ. Mecanisme de ac\u021biune \u0219i aplica\u021bii terapeutice ale peptidei glucagon-like 1. <em>Metabolismul celular<\/em>. 2018;27(4):740-756.<br>Nauck MA, Meier JJ. Hormonii incretini: Rolul lor \u00een s\u0103n\u0103tate \u0219i boal\u0103. <em>Diabet, Obezitate \u0219i Metabolism<\/em>. 2019.<br>Marso SP \u0219i colab. Semaglutida \u0219i rezultatele cardiovasculare la pacien\u021bii cu diabet zaharat de tip 2. <em>New England Journal of Medicine<\/em>. 2016.<br>Wilding JPH et al. Semaglutid\u0103 s\u0103pt\u0103m\u00e2nal\u0103 la adul\u021bi cu supraponderabilitate sau obezitate. <em>New England Journal of Medicine<\/em>. 2021.<br>Frias JP et al. Tirzepatid\u0103 versus Semaglutid\u0103 administrate s\u0103pt\u0103m\u00e2nal la pacien\u021bii cu diabet de tip 2. <em>New England Journal of Medicine<\/em>. 2021.<br>Jastreboff AM \u0219i colab. Tirzepatid\u0103 o dat\u0103 pe s\u0103pt\u0103m\u00e2n\u0103 pentru tratamentul obezit\u0103\u021bii. <em>New England Journal of Medicine<\/em>. 2022.<br>Jastreboff AM \u0219i colab. Agonistul Receptorilor Tripli de Hormoni Retatrutida pentru Obezitate \u2014 Studiu de Faza 2. <em>New England Journal of Medicine<\/em>. 2023.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">11. Compusi metabolici de cercetare \u00eenruditi<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"\/ro\/product\/semaglutide-10-mg\/\" data-type=\"product\" data-id=\"303\">Semaglutid\u0103 (agonist al receptorilor GLP-1)<\/a><\/li>\n\n\n\n<li><a href=\"\/ro\/product\/tirzepatide-10-mg\/\" data-type=\"product\" data-id=\"309\">Tirzepatid\u0103 (Agonist dual GLP-1\/GIP)<\/a><\/li>\n\n\n\n<li><a href=\"\/ro\/product\/retatrutide-10-mg\/\" data-type=\"product\" data-id=\"331\">Retatrutid\u0103 (analog triplu agonist)<\/a><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Exploreaz\u0103 complet <a href=\"\/ro\/category\/peptidi-de-cercetare-metabolica\/\" data-type=\"product_cat\" data-id=\"19\"><strong>Cercetare metabolic\u0103<\/strong> <\/a>categorii pentru formatele \u0219i specifica\u021biile disponibile.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>","protected":false},"excerpt":{"rendered":"<p>GLP-1, dual &amp; triple agonists in metabolic research Mechanisms, structural engineering &amp; comparative analysis Metabolic research peptides targeting incretin pathways represent one of the most intensively studied areas in modern endocrine and energy-regulation research. GLP-1 receptor agonists and multi-agonist analogues are widely investigated for their role in glucose homeostasis, appetite signaling, lipid metabolism, and systemic [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-529","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/life-peptide.com\/ro\/wp-json\/wp\/v2\/pages\/529","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/life-peptide.com\/ro\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/life-peptide.com\/ro\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/life-peptide.com\/ro\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/life-peptide.com\/ro\/wp-json\/wp\/v2\/comments?post=529"}],"version-history":[{"count":7,"href":"https:\/\/life-peptide.com\/ro\/wp-json\/wp\/v2\/pages\/529\/revisions"}],"predecessor-version":[{"id":989,"href":"https:\/\/life-peptide.com\/ro\/wp-json\/wp\/v2\/pages\/529\/revisions\/989"}],"wp:attachment":[{"href":"https:\/\/life-peptide.com\/ro\/wp-json\/wp\/v2\/media?parent=529"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}